<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072111</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000335469</org_study_id>
    <secondary_id>NCI-03-C-0281</secondary_id>
    <nct_id>NCT00072111</nct_id>
    <nct_alias>NCT00068016</nct_alias>
  </id_info>
  <brief_title>Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene</brief_title>
  <official_title>Phase I Study of Anakinra Mediated Tumor Regression and Angiogenesis Inhibition in Subjects With Cancers Producing Interleukin-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as anakinra, may interfere with the growth of the tumor&#xD;
      cells and slow the growth of metastatic tumors that express the interleukin-1 gene.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of anakinra in&#xD;
      treating patients with metastatic cancer that expresses the interleukin-1 gene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of anakinra in patients&#xD;
           with metastatic cancer expressing the interleukin-1 gene.&#xD;
&#xD;
        -  Determine the steady state pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the antitumor efficacy of this drug in these patients.&#xD;
&#xD;
        -  Determine gene expression changes in tumor biopsies and circulating leukocyte and&#xD;
           cytokine levels in these patients before and after treatment with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive anakinra subcutaneously 1-3 times daily on days 1-28. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of anakinra until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6&#xD;
      patients are treated at that dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anakinra</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic cancer&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Able to be percutaneously biopsied with minimum morbidity on protocol&#xD;
                  NCI-99-C-0128&#xD;
&#xD;
          -  Tumor expression of interleukin-1 by biopsy&#xD;
&#xD;
          -  Progressive disease during prior standard first-line chemotherapy OR refused standard&#xD;
             first-line chemotherapy&#xD;
&#xD;
          -  No active intracranial or leptomeningeal metastases&#xD;
&#xD;
               -  Prior radiotherapy to or resection of intracranial metastatic disease allowed&#xD;
                  provided there is no evidence of active disease on MRI or CT scan for the past&#xD;
                  month AND there is no requirement for concurrent anticonvulsant or steroid&#xD;
                  medications&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  PT within 2 seconds of the upper limit of normal&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.6 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 30 mL/min&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No allergy to proteins made from bacteria&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 30 days since prior biologic therapy&#xD;
&#xD;
          -  No concurrent systemic immune modulators&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 30 days since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 14 days since prior localized radiotherapy to non-target lesions and&#xD;
             recovered&#xD;
&#xD;
          -  More than 30 days since other prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 30 days since prior antibiotic therapy for infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K. Libutti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

